

The Innovative Medicines Initiative



Creating Biomedical R&D Leadership for Europe

EuroNanoPar Workshop
Karen Strandgaard




The Drivers for a New R&D Model Based on Public-Private Partnership



- The need to enhance European's competitiveness;
- Timelines and cost of drug development;
- The potential of increased cooperation between stakeholders;
- Wealth of novel opportunities from new science and technologies.

2

Science and technology advances present significant opportunities



3

The IMI Strategic Research Agenda


<http://www.imi-europe.org>



- Identifies pre-competitive bottlenecks in the R&D process;
- Proposes recommendations to address these bottlenecks;
- Proposes a new model of Public-Private collaborations to implement these recommendations.

4

Broad Consultation to develop the IMI Strategic Research Agenda



Total of 350 participants

5

Benefits of IMI for the Biopharmaceutical Industry



- Increased collaboration with all relevant stakeholders;
- Faster interpretation of safety findings through sharing pre-competitive toxicology data;
- Reduction of animal use in safety evaluation;
- Validation of new assessment methods e.g. biomarkers;
- Fewer patients needed in pivotal trials;
- Faster approvals through better collaboration with EMEA;
- Fewer post-marketing withdrawals;
- More skilled professionals.

➔ **More cost-efficient R&D**

6

Benefits of IMI for Academia



- Source of funding for research
- Improved infrastructure with state-of-the-art technological equipment
- Access to pre-competitive knowledge that was previously out of reach
- Increased mobility between the public and private sectors
- Increase co-ordination internationally on medical research topics
- Faster application of research results
- Increased collaboration with all relevant stakeholders

→ **More funding for research**

7

Benefits of Increased Collaboration for All Stakeholders



- Access to pre-competitive knowledge that was previously out of reach
- Stimulation of creativity
- Achievement of critical mass
- Shared risk of failure
- Enhanced learning experience

→ **Generation of More Innovative Solutions**

8

Benefits of IMI for Member States



- Leverage national Research infrastructure through good EU co-ordination;
- More jobs in the EU, achieving the Lisbon objective;
- Increased economic value through small and large enterprises in Europe;
- More education and training in the biomedical arena;
- Decrease the brain drain by strengthening the European science base helping countries retain and attract scientific talent

→ **Healthier society and citizens**

9

Complementarities and synergies must be exploited



EU National Initiatives

US Initiatives

Japan Initiatives

Global Standardisation Initiatives

European Brain Council

European Society Study Diabetes

Other academic associations



DG Research Collaborative Projects

DG Research Infrastructure Projects

DG INFSO Collaborative Projects

10

IMI Estimated Timelines to implementation in 2007



- Preparation of the IMI legal package February
- Interservices Consultation March
- Adoption by the European Commission April
- Submission to the European Council May
- Consultation of the European Parliament May
- Opinion by the European Parliament October
- Approval by the European Council November
- First call for proposals December

11

How is IMI going strengthen the European science base?



- Increase knowledge about diseases and biomedical tools,
- Increase education and training in the biomedical arena,
- Foster small and medium sized enterprises in Europe,
- Create more R&D jobs in the EU in the public and private sectors,
- Retain talents in the EU

12

How to Provide More Effective, Safer Medicines Faster?



- IMI is about R&D processes from target identification to pharmacovigilance;
- IMI is about tools and understanding of diseases, not about medicinal products;
- IMI is a unique public and private sector collaboration based on science and transparency;
- Member States have a critical role to play to make IMI a success for all citizens.

13

For EFPIA, IMI is the top priority for 2007



14

The Innovative Medicines Initiative



The End